1 -Gorbalenya, Alexander E., et al. "Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group." (2020).doi.org// 10.1101/2020.02.07.937862v1
2 - Chan, J. W. M., et al. "Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)." Thorax 58.8 (2003): 686-689.
3 -World Health Organization. Rolling updates on coronavirus disease (COVID-19). Available online:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed on24 April 2020).
4 -Booth, Timothy F., et al. "Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units." The Journal of infectious diseases 191.9 (2005): 1472-1477.
5 -Cascella, Marco, et al. "Features, evaluation and treatment coronavirus (COVID-19)." Statpearls [internet]. StatPearls Publishing, 2020.
6 - Huang, Chaolin, et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China." The Lancet 395.10223 (2020): 497-506.
7 - Wang, Dawei, et al. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China." Jama 323.11 (2020): 1061-1069.
8 - Chen, Nanshan, et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study." The Lancet 395.10223 (2020): 507-513.
9 -Zhou, Fei, et al. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study." The Lancet (2020).doi.org/10.1016/S0140-6736(20)30566-3
10 - Spina, Stefano, et al. "The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy." The Lancet 395.10227 (2020): e49-e50.
11 - Grasselli, Giacomo, Antonio Pesenti, and Maurizio Cecconi. "Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response." Jama 323.16(2020): 1545-1546.
12 - Onder, Graziano, Giovanni Rezza, and Silvio Brusaferro. "Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy." Jama 323.18 (2020): 1775-1776.
13 -Remuzzi, Andrea, and Giuseppe Remuzzi. "COVID-19 and Italy: what next?." The Lancet (2020).doi.org/10.1016/S0140-6736(20)30627-9
14 - Ruan, Qiurong, et al. "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China." Intensive care medicine 46.5 (2020): 846-848.
15 - Li, Qun, et al. "Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia." New England Journal of Medicine (2020).
DOI: 10.1056/NEJMoa2001316
16 -Yang, Ai-Ping, et al. "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients." International immunopharmacology (2020): 106504.doi.org/10.1016/j.intimp.2020.106504
17-Zhu, Na, et al. "A novel coronavirus from patients with pneumonia in China, 2019." New England Journal of Medicine (2020). DOI: 10.1056/NEJMoa2001017
18- Wang, Fu-Sheng, and Chao Zhang. "What to do next to control the 2019-nCoV epidemic?." The Lancet 395.10222 (2020): 391-393.
19-Yan, Xisheng, et al. "Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross‐sectional study." Journal of Medical Virology (2020).doi.org/10.1002/jmv.26061
20-Sun, Suyu, et al. "Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China." Clinica Chimica Acta (2020).doi.org/10.1016/j.cca.2020.04.024
21-Mo, Pingzheng, et al. "Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China." Clinical Infectious Diseases (2020).doi.org/10.1093/cid/ciaa270
22- Chen, Nanshan, et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study." The Lancet 395.10223 (2020): 507-513.
23-Qin, Chuan, et al. "Dysregulation of immune response in patients with COVID-19 in Wuhan, China." Clinical Infectious Diseases (2020).doi.org/10.1093/cid/ciaa248
24- Zhu, Minsheng. "SARS immunity and vaccination." Cell Mol Immunol 1.3 (2004): 193-198.
25-Zhang, Jin-jin, et al. "Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China." Allergy (2020).doi.org/10.1111/all.14238
26- Du, Yingzhen, et al. "Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study." American journal of respiratory and critical care medicine 201.11 (2020): 1372-1379.
27-Lindsley, Andrew W., Justin T. Schwartz, and Marc E. Rothenberg. "Eosinophil responses during COVID-19 infections and coronavirus vaccination." Journal of Allergy and Clinical Immunology (2020).doi.org/10.1016/j.jaci.2020.04.021
28- Bass, DAVD A. "Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation." The Journal of clinical investigation 56.4 (1975): 870-879.
29- Hassani, Marwan, et al. "Differentiation and activation of eosinophils in the human bone marrow during experimental human endotoxemia." Journal of Leukocyte Biology (2020).https://doi.org/10.1002/JLB.1AB1219-493R
30- Butterfield, Joseph H. "Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon." Immunology and allergy clinics of North America 27.3 (2007): 493-518.
31- Albright, Joslyn M., et al. "Advanced age alters monocyte and macrophage responses." Antioxidants & redox signaling 25.15 (2016): 805-815.
32- Pence, Brandt D. "Severe COVID-19 and aging: are monocytes the key?." GeroScience (2020): 1-11.
33- Audimooolam, Vinod K., et al. "Elevated troponin I and its prognostic significance in acute liver failure." Critical Care 16.6 (2012): R228.
34- Fortunato, Antonio, and Davide Giavarina. "Decision limit for troponin I on ADVIA: Centaur and evaluation of the analytical precision at low concentrations." Clinical Laboratory 49.5-6 (2003): 251-253.
35- Cardinale, Daniela, et al. "Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy." Circulation 109.22 (2004): 2749-2754.
36- Hamm, Christian W., Evangelos Giannitsis, and Hugo A. Katus. "Cardiac troponin elevations in patients without acute coronary syndrome." (2002): 2871-2872.
37- Chapman, Andrew R., Anda Bularga, and Nicholas L. Mills. "High-sensitivity cardiac troponin can be an ally in the fight against COVID-19." Circulation 141.22 (2020): 1733-1735.
38- Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." New England journal of medicine 382.18 (2020): 1708-1720.
39-Zhou, Fei, et al. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study." The lancet (2020).doi.org/10.1016/S0140-6736(20)30566-3
40- Agewall, S., et al. "Troponin elevation in coronary vs. non-coronary disease." European heart journal 32.4 (2011): 404-411.